Zentalis Pharmaceuticals (ZNTL) Accumulated Expenses (2019 - 2026)

Zentalis Pharmaceuticals' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $27.9 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 33.13% year-over-year to $27.9 million in Q1 2026; TTM through Mar 2026 was $27.9 million, a 33.13% decrease from a year earlier, with the FY2025 full-year figure at $29.4 million, down 35.19% from the prior year.
• Accumulated Expenses slipped to $27.9 million in Q1 2026 per ZNTL's latest filing, from $29.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $54.4 million in Q4 2023 and bottomed at $27.9 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $43.5 million (2023), against an average of $40.3 million.
• Across the five-year window, Accumulated Expenses soared 44.62% in 2022 and sank 35.43% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $45.4 million in 2022, then gained by 19.91% to $54.4 million in 2023, then decreased by 16.81% to $45.3 million in 2024, then plunged by 35.19% to $29.4 million in 2025, then slipped by 5.09% to $27.9 million in 2026.
• Per Business Quant, the three latest ZNTL Accumulated Expenses figures stand at $27.9 million (Q1 2026), $29.4 million (Q4 2025), and $30.1 million (Q3 2025).